July 20, 2020 -- Sorrento Therapeutics received clearance from the U.S. Food and Drug Administration to initiate a phase II clinical trial evaluating abivertinib for treatment of moderate and severe COVID-19 patients.
The tyrosine kinase inhibitor, licensed from Acea Therapuetics, is a potent immunomodulator that inhibits pro-inflammatory cytokine production, including interleukin 1 beta (IL-1beta), IL-6, and tumor necrosis factor alpha (TNF alpha). These cytokines have been associated with cytokine storms and COVID-19 progression with poor outcomes in patients with acute respiratory distress syndrome (ARDS).
The phase II, double-blind, randomized clinical study (NCT04440007) will be initially conducted in the U.S.
Abivertinib has previously been studied in over 600 patients with various oncologic indications.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: